The aim is to estimate an oral administered recommended dose of BP-C2 in addition to hormone
treatment of prostate cancer.
The study population consists of prostatic cancer patients between 18 and 80 years of age
undergoing hormonal treatment. Four patients will be recruited consecutively from each of two
participating hospital.
The study will be performed as an open, one-dimensional multi-center trial with a 3-level
within-patient Response Surface Pathway (RSP) design.